Rezolute Awaits FDA Review of Ersodetug in Congenital HI
REDWOOD CITY, Calif. — September 9, 2026 Rezolute, Inc. provided an update on the U.S. Food and Drug Administration’s...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
REDWOOD CITY, Calif. — September 9, 2026 Rezolute, Inc. provided an update on the U.S. Food and Drug Administration’s...
ABBOTT PARK, Ill., August 25, 2026 Abbott announced that the U.S. Food and Drug Administration (FDA) has authorized Libre...
San Diego, July 22, 2026 Dexcom announced that it has become the first company selected by the U.S. Food...
REDWOOD CITY, Calif., May 01, 2026 Rezolute, Inc. has announced detailed results from its Phase 3 sunRIZE study evaluating...
